Outlook’s Ophthalmic Bevacizumab Knocked Back By FDA
US Agency Offers Multiple Reasons For CRL Over Outlook’s BLA For Lytenava
Outlook Therapeutics has received a CRL from the US FDA over its application for an ophthalmic formulation of bevacizumab. The company says it is working with the agency to address the various issues raised.
